DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines

International Journal of Cancer

Volumn 130, Issue 2, 2012, Pages 267-277

  Kadowaki, Mitsutoshi ^a,b   Yoshioka, Hiroki ^b   Kamitani, Hideki ^b   Watanabe, Takashi ^b   Wade, Paul A ^a   Eling, Thomas E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

DNA methylation; GDF15; glioblastoma; NAG 1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; EARLY GROWTH RESPONSE FACTOR 1; GROWTH DIFFERENTIATION FACTOR 15; NONSTEROID ANTIINFLAMMATORY AGENT; NONSTEROID ANTIINFLAMMATORY DRUG ACTIVATED GENE 1; SULINDAC SULFIDE; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ASTROCYTE; BINDING SITE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA ISOLATION; DNA METHYLATION; EPIGENETICS; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HISTONE MODIFICATION; HUMAN; HUMAN CELL; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION; TUMOR GROWTH;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; AZACITIDINE; BRAIN NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA METHYLATION; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; HYDROXAMIC ACIDS; PROMOTER REGIONS, GENETIC; SULINDAC; TRANSFECTION;

EID: 83655167375     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26082     Document Type: Article

References (39)

1. Mischel PS, Cloughesy TF, Nelson SF,. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev 2004; 5: 782-92.
2. Ohgaki H, Kleihues P,. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109: 93-108.
3. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-9.
4. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H,. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997; 3: 523-30.
5. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H,. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-23; discussion 23-4.
6. Dahia PL,. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 2000; 7: 115-29.
7. Nakamura M, Sakaki T, Hashimoto H, Nakase H, Ishida E, Shimada K, Konishi N,. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res 2001; 61: 6335-9.
8. Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H,. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 2001; 81: 77-82.
9. Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kleihues P,. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 1995; 427: 113-18.
10. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
11. Jennings MT, Pietenpol JA,. The role of transforming growth factor beta in glioma progression. J Neurooncol 1998; 36: 123-40.
12. Naumann U, Maass P, Gleske AK, Aulwurm S, Weller M, Eisele G,. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. Int J Oncol 2008; 33: 759-65.
13. Kondo Y, Issa JP,. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 2004; 23: 29-39.
14. Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD,. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006; 66: 7490-501.
15. Yi JM, Tsai HC, Glockner SC, Lin S, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 2008; 68: 8094-103.
16. Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 2006; 66: 159-67.
17. Fairlie WD, Moore AG, Bauskin AR, Russell PK, Zhang HP, Breit SN,. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol 1999; 65: 2-5.
18. Martinez JM, Sali T, Okazaki R, Anna C, Hollingshead M, Hose C, Monks A, Walker NJ, Baek SJ, Eling TE,. Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate- derived factor, a putative tumor suppressor, inhibits tumor growth. J Pharmacol Exp Ther 2006; 318: 899-906.
19. Schober A, Bottner M, Strelau J, Kinscherf R, Bonaterra GA, Barth M, Schilling L, Fairlie WD, Breit SN, Unsicker K,. Expression of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in the perinatal, adult, and injured rat brain. J Comp Neurol 2001; 439: 32-45.
20. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 2003; 100: 3410-15.
21. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE,. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59: 901-8.
22. Baek SJ, Okazaki R, Lee SH, Martinez J, Kim JS, Yamaguchi K, Mishina Y, Martin DW, Shoieb A, McEntee MF, Eling TE,. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006; 131: 1553-60.
23. Baek SJ, Eling TE,. Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog Lipid Res 2006; 45: 1-16.
24. Strelau J, Sullivan A, Bottner M, Lingor P, Falkenstein E, Suter-Crazzolara C, Galter D, Jaszai J, Krieglstein K, Unsicker K,. Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo. J Neurosci 2000; 20: 8597-603.
25. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004; 10: 2386-92.
26. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ, Breit SN,. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003; 63: 5034-40.
27. Yoshioka H, Kamitani H, Watanabe T, Eling TE,. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J Biol Chem 2008; 283: 33129-37.
28. Strelau J, Schmeer C, Peterziel H, Sackmann T, Herold-Mende C, Steiner H, Weller M, Unsicker K,. Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines. Cancer Lett 2008; 270: 30-9.
29. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-22.
30. Baek SJ, Wilson LC, Eling TE,. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002; 23: 425-34.
31. Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
32. Grothey A, Ellis LM,. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J 2008; 14: 170-7.
33. Maity A, Bernhard EJ,. Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy. Cancer Res 2010; 70: 2141-5.
34. Rath P, Shi H, Maruniak JA, Litofsky NS, Maria BL, Kirk MD,. Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas. Curr Stem Cell Res Ther 2009; 4: 44-9.
35. Witt O, Schweigerer L, Driever PH, Wolff J, Pekrun A,. Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 2004; 43: 181.
36. Stone AR, Bobo W, Brat DJ, Devi NS, Van Meir EG, Vertino PM,. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol 2004; 165: 1151-61.
37. Baek SJ, Kim JS, Nixon JB, DiAugustine RP, Eling TE,. Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 2004; 279: 6883-92.
38. Yamaguchi K, Lee SH, Eling TE, Baek SJ,. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J Biol Chem 2004; 279: 49617-23.
39. Bottone FG, Jr, Baek SJ, Nixon JB, Eling TE,. Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J Nutr 2002; 132: 773-8.